Levels of GAT-TALAD and AFP showed no significant difference between CCA patients and patients with benign liver diseases (Table 2), and the efficacy (AUC) of GAP-TALAD in diagnosing early HCC and non-HCC (CCA and benign liver diseases) was significantly higher than that of AFP (p = 0.0032; Table 5, Fig. 5B). Here, AFP is linked to hepatocellular carcinoma.